Patents Assigned to Hoffmann-La Roche Inc.
-
Publication number: 20250115607Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 18, 2024Publication date: April 10, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Xavier LUCAS CABRÉ, Etienne RAUBER
-
Publication number: 20250116656Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: October 20, 2023Publication date: April 10, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
-
Publication number: 20250114775Abstract: The invention comprises a process for the preparation of a [Ru(OAc)2(Ligand)] catalysts of the formula I wherein R1 is C1-6 alkyl and R3 is hydrogen or C1-6 alkyl and R4 is hydrogen or C1-6-alkoxy. [Ru(OAc)2(Ligand)] catalysts are versatile hydrogenation catalysts.Type: ApplicationFiled: December 17, 2024Publication date: April 10, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Kurt PUENTENER, Etienne TRACHSEL
-
Patent number: 12269867Abstract: Herein is reported a method for the enzymatic preparation/production of an antibody with a modified glycosylation in the Fc-region comprises the steps of incubating an antibody that has a glycosylation in the Fc-region with one or more enzymes for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region to a defined form, separating in one or more chromatography steps the antibody with a modified glycosylation in the Fc-region from the one or more enzymes and thereby producing the antibody with a modified glycosylation in the Fc-region and one or more recycled enzymes, and repeating the incubating step with the one or more recycled enzymes at least once.Type: GrantFiled: June 20, 2019Date of Patent: April 8, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Roberto Falkenstein, Sebastian Malik, Ingrid Grunert, Marco Thomann, Matthias Freiherr Von Roman, Heiko Walch
-
Publication number: 20250109166Abstract: The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof, wherein PG1, PG2 and PG3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.Type: ApplicationFiled: August 13, 2024Publication date: April 3, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Jean-Michel Adam, Fritz Bliss, Pascal Jean Claude Dott, Fabienne Roxane Hoffmann-Emery, Ulf Göran Larsson, Kurt Puentener
-
Publication number: 20250109149Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.Type: ApplicationFiled: September 13, 2024Publication date: April 3, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Roland MEIER, Urs SCHWITTER, Anne DE PAEPE, Peter KUEHL, Juergen THUN, Frank STOWASSER
-
Patent number: 12264196Abstract: The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.Type: GrantFiled: October 2, 2019Date of Patent: April 1, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Thomas Regula, Wolfgang Schaefer, Tilman Schlothauer
-
Publication number: 20250101135Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: ApplicationFiled: June 10, 2024Publication date: March 27, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Regula, Pablo Umana
-
Publication number: 20250099448Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described heroin, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: January 25, 2023Publication date: March 27, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Machoud AMOUSSA, Joerg BENZ, Julie Elisabeth Francoise BLAISING, Jason Jacques DENIZOT, Kallie FRISTON, Rudolf Liun Zaccaria GANZONI, Maude GIROUD, Uwe GRETHER, Benoit HORNSPERGER, Isabelle KAUFMANN, Bernd KUHN, Camiel John LEAKE, Jacopo MARGARINI, Rainer Eugen MARTIN, Fionn Susannah O'HARA, Bernd PUELLMANN, Martin RITTER, Didier ROMBACH, Valerie RUNTZ-SCHMITT, Philipp Claudio SCHMID, Matthias Beat WITTWER
-
Publication number: 20250101132Abstract: The present invention relates to the combination therapy of a bispecific antibody which binds human TYRP1 and CD3 and a second TYRP1-specific antibody.Type: ApplicationFiled: May 20, 2024Publication date: March 27, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Christian KLEIN, Valeria G. NICOLINI, Pablo UMAÑA
-
Patent number: 12260944Abstract: The application relates to devices and methods for determining an administration regimen of a drug to a subject. Determining an administration regimen for a subject comprises computing the amount of drug to be administered to the subject per elemental period of time, and determining and evaluating combinations of at least two dosage forms that can be used to administered the amount of drug, against at least two different criteria. The methods of the invention find applications in the selection of administration regimen for drugs that are available in multiple dosage forms, and especially drugs that are administered routinely over prolonged periods, such as e.g. in the routine prophylaxis of haemophilia.Type: GrantFiled: October 7, 2020Date of Patent: March 25, 2025Assignee: HOFFMANN-LA-ROCHE INC.Inventors: Geraint Iwan Davies, David Elfant, Martin Jenkins
-
Patent number: 12259380Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: February 22, 2023Date of Patent: March 25, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20250092128Abstract: The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.Type: ApplicationFiled: September 30, 2024Publication date: March 20, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Peter BRUENKER, Martina GEIGER, Christian KLEIN, Pablo UMAÑA
-
Publication number: 20250092136Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: July 25, 2024Publication date: March 20, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Alexander Christian BUJOTZEK, Christian Robert GASSNER, Christian KLEIN, Stéphane Gérard Alain LECLAIR, Stephan MAERSCH, Ekkehard MOESSNER, Inja WALDHAUER
-
Publication number: 20250093367Abstract: The current invention is directed to a method for determining homodimeric avid-binding side-products of a bispecific antibody in a sample comprising the correctly assemble heterodimeric affine-binding bispecific antibody and the mis-assembled homodimeric avid-binding side-product of the bispecific antibody using surface plasmon resonance, wherein the correctly assembled heterodimeric affine-binding bispecific antibody comprises one or more binding site for a first antigen and one or more binding sites for a second antigen, wherein the mis-assembled homodimeric avid-binding side-product of the bispecific antibody comprises two or more binding sites to the first antigen but at least more than the correctly assembled bispecific antibody, wherein the correctly assembled bispecific antibody is a heterodimer and the mis-assembled bispecific antibody is a homodimer, wherein the presence of the homodimeric avid-binding side-product is determined if residual binding, i.e.Type: ApplicationFiled: May 23, 2024Publication date: March 20, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Laurent LARIVIERE, Tilman SCHLOTHAUER, Christian SPICK, Adrian ZWICK
-
Patent number: 12252484Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.Type: GrantFiled: September 6, 2018Date of Patent: March 18, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Fabian Dey, Taishan Hu, Haixia Liu, Hong Shen, Zhiwei Zhang, Wei Zhu
-
Patent number: 12252533Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.Type: GrantFiled: December 21, 2022Date of Patent: March 18, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
-
Publication number: 20250084086Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided.Type: ApplicationFiled: August 7, 2024Publication date: March 13, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Stephan BACHMANN, Lukas CHYTIL, Serena Maria FANTASIA, Alec FETTES, Ursula HOFFMANN
-
Publication number: 20250087302Abstract: Methods for facilitating selection of cell lines for production of recombinant proteins are disclosed. In particular, disclosed is the use of machine learning models trained on multiomics data to predict one or more values indicative of the titre and/or quality of a recombinant protein expressed by different cell lines, enabling ranking the cell lines based on the predicted values and selecting those predicted to produce the recombinant protein with higher titre and/or higher quality.Type: ApplicationFiled: September 11, 2024Publication date: March 13, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Shan-Hua CHUNG, Daniel Tobias GROSSKOPF, Styliani PAPADAKI, Oliver Helmut POPP, Tom Kamran QUAISER, Laura Susanne STOECKL, Styliani TOURNAVITI
-
Publication number: 20250084102Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.Type: ApplicationFiled: August 7, 2024Publication date: March 13, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Jean-Michel ADAM, Serena Maria FANTASIA, Daniel Vincent FISHLOCK, Fabienne HOFFMANN-EMERY, Gerard MOINE, Christophe PFLEGER, Christian MOESSNER